Edesa Stock Today

EDSA -  USA Stock  

USD 8.24  0.14  1.76%

Edesa Biotech is trading at 8.24 as of the 27th of September 2021, a 1.76% increase since the beginning of the trading day. The stock's open price was 8.0974. Edesa Biotech has about a 43 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Edesa Biotech are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 8th of October 2019 and ending today, the 27th of September 2021. Please note, there could be an existing legal relationship between Edesa Biotech (EDSA) and Edesa Biotech (SBOT). Click here to learn more.
 Market Performance
7 of 100
  Odds Of Distress
Less than 43

Edesa Biotech Stock Profile

The next fiscal quarter end is expected on the 30th of September 2021. Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada. Edesa Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 12 people. more on Edesa Biotech
Edesa Biotech is way too risky over 90 days horizon
Edesa Biotech appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 110.48 K. Net Loss for the year was (8.68 M) with profit before overhead, payroll, taxes, and interest of 311.2 K.
Edesa Biotech currently holds about 10.97 M in cash with (13.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.83.
Edesa Biotech has a very weak financial position based on the latest SEC disclosures
Roughly 33.0% of the company shares are held by company insiders
Latest headline from www.equities.com: Edesa falls 1.44 percent in Light Trading on September 22 - Equities.com
Edesa Biotech Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Edesa Biotech SEC Filings
Edesa Biotech SEC Filings Security & Exchange Commission EDGAR Reports
Legal NameEdesa Biotech
Related EntitySBOT (Edesa Biotech)
Thematic Classification
Currently Active Investing Idea (view all)
  Pharmaceutical Products
Average Analyst Recommendation
Analysts covering Edesa Biotech report their recommendations after researching Edesa Biotech's financial statements, talking to executives and customers, or listening in on Edesa Biotech's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Edesa Biotech. The Edesa consensus assessment is calculated by taking the average forecast from all of the analysts covering Edesa Biotech.
Strong Buy1 Opinion
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Edesa Biotech based on its profitability, leverage, liquidity, source of funds, and operating efficiency. it is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Edesa Biotech financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 1 - Very WeakDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares3.5 M3.2 M
Significantly Up
Slightly volatile
Weighted Average Shares Diluted3.5 M3.2 M
Significantly Up
Slightly volatile
Total Assets3.5 M3.4 M
Fairly Up
Slightly volatile
Total Liabilities188.7 K183.8 K
Fairly Up
Slightly volatile
Current Assets3.5 M3.4 M
Fairly Up
Slightly volatile
Current Liabilities188.7 K183.8 K
Fairly Up
Slightly volatile
Total Debt146.9 K147.8 K
Slightly Down
Slightly volatile
Gross Margin(1.07)(1.043)
Fairly Down
Very volatile
Asset Turnover0.0950.108
Fairly Down
Very volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Edesa Biotech's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Financial Strength
Edesa Biotech's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Edesa Biotech's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Edesa Biotech's financial leverage. It provides some insight into what part of Edesa Biotech's total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Edesa Biotech's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Edesa Biotech deploys its capital and how much of that capital is borrowed.
Edesa Biotech cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 138.14 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Edesa Biotech has a current ratio of 4.55, suggesting that it is liquid enough and is able to pay its financial obligations when due.

Operating Cash Flow

(1.39 Million)Share
Edesa Biotech (EDSA) is traded on NASDAQ Exchange in USA. It is located in 100 Spy Court and employs 12 people. Edesa Biotech is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with current market capitalization of 109.23 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Edesa Biotech's market, we take the total number of its shares issued and multiply it by Edesa Biotech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Edesa Biotech conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 13.26 M outstanding shares of which 52.63 K shares are currently shorted by private and institutional investors with about 0.2 trading days to cover. Edesa Biotech currently holds about 10.97 M in cash with (13.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.83.
Check Edesa Biotech Probability Of Bankruptcy
The market capitalization of Edesa Biotech is $109.23 Million. Edesa Biotech retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.

Ownership Allocation (%)

Check Edesa Ownership Details

Edesa Stock Price Odds Analysis

What are Edesa Biotech's target price odds to finish over the current price? Depending on a normal probability distribution, the odds of Edesa Biotech jumping above the current price in 90 days from now is near 1%. The Edesa Biotech probability density function shows the probability of Edesa Biotech stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.67 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Edesa Biotech will likely underperform. Moreover, the company has an alpha of 1.2304, implying that it can generate a 1.23 percent excess return over DOW after adjusting for the inherited market risk (beta).
 Odds Down 8.24HorizonTargetOdds Up 8.24 
99.62%90 days
Based on a normal probability distribution, the odds of Edesa Biotech to move above the current price in 90 days from now is near 1 (This Edesa Biotech probability density function shows the probability of Edesa Stock to fall within a particular range of prices over 90 days) .

Edesa Biotech Historical Income Statement

Edesa Biotech Income Statement is one of the three primary financial statements used for reporting Edesa's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Edesa Biotech revenue and expense. Edesa Biotech Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Edesa Biotech Operating Expenses is projected to decrease significantly based on the last few years of reporting. The past year's Operating Expenses was at 1.62 Million. The current year Revenues is expected to grow to about 432.1 K, whereas Consolidated Income is forecasted to decline to (1.7 M). View More Fundamentals

Edesa Stock Against Markets

Picking the right benchmark for Edesa Biotech stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Edesa Biotech stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Edesa Biotech is critical whether you are bullish or bearish towards Edesa Biotech at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Edesa Biotech without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Fundamentals Comparison Now


Fundamentals Comparison

Compare fundamentals across multiple equities to find investing opportunities
All  Next Launch Module
Continue to Investing Opportunities. Note that the Edesa Biotech information on this page should be used as a complementary analysis to other Edesa Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Complementary Tools for Edesa Stock analysis

When running Edesa Biotech price analysis, check to measure Edesa Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edesa Biotech is operating at the current time. Most of Edesa Biotech's value examination focuses on studying past and present price action to predict the probability of Edesa Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Edesa Biotech's price. Additionally, you may evaluate how the addition of Edesa Biotech to your portfolios can decrease your overall portfolio volatility.
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
The market value of Edesa Biotech is measured differently than its book value, which is the value of Edesa that is recorded on the company's balance sheet. Investors also form their own opinion of Edesa Biotech's value that differs from its market value or its book value, called intrinsic value, which is Edesa Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Edesa Biotech's market value can be influenced by many factors that don't directly affect Edesa Biotech underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Edesa Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Edesa Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Edesa Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.